Aprinoia Therapeutics is a clinical-stage biotechnology company focused on developing innovative therapies for neurodegenerative diseases, particularly tauopathies including Progressive Supranuclear Palsy (PSP).
- Tau PET Imaging: Developing diagnostic PET tracers for tau pathology
- Tau-Targeting Therapies: Disease-modifying treatments for tauopathies
- Precision Medicine: Biomarker-driven patient selection for clinical trials
- APN-1607 (Florispir): Tau PET tracer approved in Taiwan for clinical use
- APN-003: Tau targeting therapeutic in preclinical development
- Diagnostic programs for early detection of tau pathology
Aprinoia's approach includes:
- Novel tau PET tracers for visualization of tau burden
- Small molecule therapeutics targeting pathological tau species
- Companion diagnostic development for patient stratification
- Academic partnerships with leading medical centers
- Pharmaceutical company collaborations for clinical development
- Research collaborations in Asia and North America
- Headquarters in Taipei, Taiwan
- Operations in United States (Boston area)
- Team with expertise in nuclear medicine, drug development, and neuroscience
This page provides information about Aprinoia Therapeutics.